What is the preferred treatment between Evenity (romosozumab) and Forteo (teriparatide) for a patient with severe osteoporosis and glucocorticoid-induced osteoporosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 3, 2025 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Evenity vs Forteo for Severe Osteoporosis with Glucocorticoid-Induced Osteoporosis

For patients with severe osteoporosis and glucocorticoid-induced osteoporosis, teriparatide (Forteo) is preferred over romosozumab (Evenity) due to its established efficacy in this specific population and better safety profile.

Treatment Recommendation Algorithm

First-line Treatment:

  1. Teriparatide (Forteo)
    • Recommended for patients with severe osteoporosis and glucocorticoid-induced osteoporosis
    • Dosage: 20 μg daily subcutaneous injection
    • Duration: Up to 2 years (maximum FDA-approved duration)
    • Requires calcium intake of 1,000-1,200 mg/day and vitamin D 600-800 IU/day

Second-line Options (if teriparatide is not appropriate):

  1. Oral bisphosphonates
  2. IV bisphosphonates
  3. Denosumab

Not Recommended:

  • Romosozumab (Evenity) - conditionally recommended against in moderate fracture risk patients due to risks of myocardial infarction, stroke, or death 1

Evidence Supporting Teriparatide for GIOP

The 2023 American College of Rheumatology guidelines for glucocorticoid-induced osteoporosis (GIOP) conditionally recommend anabolic agents like teriparatide over anti-resorptive agents for patients with very high fracture risk 2, 1. This recommendation is based on evidence showing:

  • Teriparatide increases lumbar and hip BMD and decreases vertebral fractures more effectively than alendronate at 36 months in GIOP patients 2
  • The anabolic (bone-forming) mechanism of teriparatide is particularly beneficial for severe osteoporosis cases where rapid bone formation is needed 1

For patients receiving frequent or chronic prednisone, teriparatide has demonstrated superior efficacy compared to bisphosphonates at increasing bone mineral density 1.

Limitations of Romosozumab in This Context

While romosozumab is a potent anabolic agent, the 2023 ACR guidelines conditionally recommend against using it in moderate fracture risk patients except in those intolerant of other agents 2, 1. This is due to:

  • Increased risks of myocardial infarction, stroke, or death
  • Limited safety data specifically in GIOP patients
  • Less established track record compared to teriparatide for GIOP

Monitoring and Follow-up

  • Perform BMD testing every 1-2 years with vertebral fracture assessment (VFA) or spinal X-rays 2
  • Monitor serum calcium after 1 month of treatment 3
  • Mild hypercalcemia can be managed by reducing dietary calcium supplements or adjusting teriparatide dosing frequency 3

Important Considerations

  • Duration limitation: Teriparatide should not be used for more than 2 years due to the potential risk of osteosarcoma (based on rat studies) 3
  • Sequential therapy: After completing teriparatide treatment, transition to an antiresorptive agent to maintain bone gains 1
  • Avoid concurrent therapy: Combining teriparatide with bisphosphonates may blunt the anabolic response 1, 3
  • Contraindications: Teriparatide should not be used in patients with Paget's disease, unexplained elevations of alkaline phosphatase, prior radiation therapy involving the skeleton, bone metastases, or history of skeletal malignancies

Lifestyle and Supplementation

In addition to pharmacological treatment:

  • Optimize calcium intake (1,000-1,200 mg/day) and vitamin D (600-800 IU/day)
  • Implement fall prevention strategies
  • Encourage weight-bearing and resistance exercises as tolerated
  • Recommend smoking cessation and limiting alcohol intake to 1-2 servings per day 1

By following this approach, patients with severe osteoporosis and glucocorticoid-induced osteoporosis can receive the most effective treatment to reduce fracture risk and improve bone health.

References

1
Guideline

Osteoporosis Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

2
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Related Questions

Is Forteo (teriparatide) safe for osteoporosis treatment in a patient with frontotemporal dementia, hypothyroidism, and a history of breast cancer?
What are the benefits of anabolic treatments, including Tymlos (abaloparatide) and Forteo (teriparatide), for osteoporosis management?
What is the recommended treatment approach for a 67-year-old female patient with severe osteoporosis, previously treated with Evenity (romosozumab) and currently on Forteo (teriparatide), with frequent oral prednisone use for asthma?
What is the recommended treatment regimen for anabolics therapy, such as teriparatide (parathyroid hormone), for patients with osteoporosis?
When should anabolic agents, such as teriparatide (parathyroid hormone-related protein), be started in patients with osteoporosis according to Osteoporosis Canada guidelines?
What findings, including lab results and physical exam findings, are indicative of fulminant myocarditis?
What are the steps for cardiopulmonary resuscitation with medications and orotracheal intubation?
Should a 67-year-old patient with severe osteoporosis and frequent prednisone (corticosteroid) use due to asthma exacerbations complete a 2-year course of Forteo (teriparatide) after receiving 7 months of Evenity (romosozumab)?
How is ventilator-associated dyssynchrony managed?
When should d-dimer results be waited for before proceeding with advanced imaging in patients with suspected pulmonary embolism (PE), versus proceeding directly to computed tomography (CT) pulmonary angiography in high-risk patients?
What are the potential side effects of detrusor Botox (Botulinum toxin) injections?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question